Literature DB >> 8835562

The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint.

H Mielants1, E M Veys, C Cuvelier, M De Vos, S Goemaere, L De Clercq, L Schatteman, L Gyselbrecht, D Elewaut.   

Abstract

OBJECTIVE: To study prospectively the clinical evolution of different forms of spondyloarthropathy (SpA) in relation to the evolution of gut histology in consecutive ileocolonoscopic biopsy specimens.
METHODS: Ileocolonoscopy was performed in 49 patients with SpA (34 men, 15 women). They also underwent clinical, laboratory, and radiological examinations. Two to 9 years later, a 2nd and sometimes a 3rd or 4th ileocolonoscopy was performed, and the other examinations were repeated.
RESULTS: At first ileocolonoscopy, 34 patients (69%) showed inflammatory gut lesions. At the 2nd ileocolonoscopy, 16 patients (32%) were in clinical remission; none were found to have inflammatory gut lesions. Of the 33 patients with persistent locomotor inflammation, 14 had persistent inflammatory gut lesions, predominantly the chronic type. Of these 14 patients, 6 had developed inflammatory bowel disease (IBD). None of the 15 patients with an initially normal gut histology had gut inflammation at 2nd examination. Of the 9 with initially acute lesions, 3 developed chronic lesions (1 Crohn's disease). Initial chronic lesions in 25 patients persisted in 9, of whom 5 had developed IBD. Seven of the 19 patients with non-SpA ankylosing spondylitis (non-AS-SpA) developed ankylosing spondylitis (AS); all had initially presented inflammatory gut lesions, which persisted at 2nd examination. In the 11 patients with more than 2 consecutive ileocolonoscopies, clinical remission was always associated with normal gut histology, and flares of the joint disease were related temporally to the reappearance of gut inflammation.
CONCLUSION: This study demonstrates the close relationship between gut and locomotor inflammation in SpA. Clinical remission was always associated with normal gut histology, whereas active locomotor inflammation was usually associated with the presence of gut inflammation. Absence of gut inflammation in the SpA is a good prognostic indicator, since gut inflammation or IBD never develops in these patients. Evolution of non-AS-SpA to full blown AS or of uncomplicated SpA to a form of IBD was always associated with gut inflammation at disease onset.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8835562

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  55 in total

1.  Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy.

Authors:  N Van Damme; M De Vos; D Baeten; P Demetter; H Mielants; G Verbruggen; C Cuvelier; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

2.  Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy.

Authors:  I E A Hoffman; P Demetter; M Peeters; M De Vos; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 3.  The transition of acute to chronic bowel inflammation in spondyloarthritis.

Authors:  Liesbet Van Praet; Peggy Jacques; Filip Van den Bosch; Dirk Elewaut
Journal:  Nat Rev Rheumatol       Date:  2012-04-17       Impact factor: 20.543

4.  Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis.

Authors:  Matthew L Stoll; Marilynn Punaro; Ashish S Patel
Journal:  J Rheumatol       Date:  2011-10       Impact factor: 4.666

Review 5.  The treatment of the rheumatological manifestations of the inflammatory bowel diseases.

Authors:  Melissa Padovan; Gabriella Castellino; Marcello Govoni; Francesco Trotta
Journal:  Rheumatol Int       Date:  2006-06-24       Impact factor: 2.631

6.  Human HLA-B27 gene enhances susceptibility of rats to oral infection by Listeria monocytogenes.

Authors:  T F Warner; J Madsen; J Starling; R D Wagner; J D Taurog; E Balish
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 7.  Clinical observations programme in SpA: disease parameters, treatment options and practical management issues.

Authors:  Dirk Elewaut; Filip Van den Bosch; Gust Verbruggen; Filip de Keyser; Bert Vander Cruyssen; Herman Mielants
Journal:  Rheumatol Int       Date:  2008-09-26       Impact factor: 2.631

Review 8.  Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis.

Authors:  M L Stoll
Journal:  Clin Exp Rheumatol       Date:  2011-04-19       Impact factor: 4.473

Review 9.  The role of the gut and microbes in the pathogenesis of spondyloarthritis.

Authors:  Mark Asquith; Dirk Elewaut; Phoebe Lin; James T Rosenbaum
Journal:  Best Pract Res Clin Rheumatol       Date:  2014-11-15       Impact factor: 4.098

10.  Treatment of ankylosing spondylitis: focus on etanercept.

Authors:  Tracy Frech
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.